Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics (AVTX) has 4 years of Liabilities from Discontinued Operations data on file, last reported at 10000.0 in Q3 2021.

• Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 10000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was 10000.0 (changed N/A YoY) and the FY2020 annual result came in at 1341000.0, down 23.59% from the prior year.
• Liabilities from Discontinued Operations fell to 10000.0 in Q3 2021, from 98000.0 in the prior quarter.
• In the past five years, Liabilities from Discontinued Operations ranged from a high of 7549631.0 in Q4 2018 to a low of 10000.0 in Q3 2021.
• A 4-year average of 1827105.17 and a median of 775000.0 in 2020 frame the typical range for Liabilities from Discontinued Operations.
• Annual changes were most pronounced in 2019 — Liabilities from Discontinued Operations tumbled 76.75% — and 2020, when it declined 23.59%.
• Tracing AVTX's Liabilities from Discontinued Operations over 4 years: stood at 7549631.0 in 2018, then plunged by 76.75% to 1755000.0 in 2019, then slipped by 23.59% to 1341000.0 in 2020, then plunged by 99.25% to 10000.0 in 2021.
• The last three Liabilities from Discontinued Operations figures came in at 10000.0 (Q3 2021), 98000.0 (Q2 2021), and 209000.0 (Q1 2021), per Business Quant data.